NasdaqCM:CASI

Stock Analysis Report

Executive Summary

CASI Pharmaceuticals, Inc., a pharmaceutical company, develops pharmaceutical products and various therapeutics in China, the United States, and internationally.

Rewards

Earnings are forecast to grow 60.23% per year

Risk Analysis

Has less than 1 year of cash runway

Shareholders have been diluted in the past year

Does not have meaningful revenue ($3M)



Snowflake Analysis

High growth potential with excellent balance sheet.

Share Price & News

How has CASI Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CASI has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-3.3%

CASI

1.2%

US Biotechs

1.2%

US Market


1 Year Return

-10.4%

CASI

12.4%

US Biotechs

24.2%

US Market

Return vs Industry: CASI underperformed the US Biotechs industry which returned 10.9% over the past year.

Return vs Market: CASI underperformed the US Market which returned 24.7% over the past year.


Shareholder returns

CASIIndustryMarket
7 Day-3.3%1.2%1.2%
30 Day0%0.2%3.5%
90 Day-9.1%17.5%11.7%
1 Year-10.4%-10.4%13.4%12.4%26.9%24.2%
3 Year153.2%153.2%30.1%25.8%53.0%43.2%
5 Year88.9%88.9%2.6%-2.3%75.3%56.0%

Price Volatility Vs. Market

How volatile is CASI Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is CASI Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

3.82x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate CASI's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate CASI's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: CASI is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: CASI is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CASI's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CASI is overvalued based on its PB Ratio (4x) compared to the US Biotechs industry average (3.2x).


Next Steps

Future Growth

How is CASI Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

60.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CASI is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).

Earnings vs Market: CASI is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: CASI's is expected to become profitable in the next 3 years.

Revenue vs Market: CASI's revenue (47.7% per year) is forecast to grow faster than the US market (7.5% per year).

High Growth Revenue: CASI's revenue (47.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CASI's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has CASI Pharmaceuticals performed over the past 5 years?

-14.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CASI is currently unprofitable.

Growing Profit Margin: CASI is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CASI is unprofitable, and losses have increased over the past 5 years at a rate of -14.7% per year.

Accelerating Growth: Unable to compare CASI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CASI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (103.3%).


Return on Equity

High ROE: CASI has a negative Return on Equity (-42%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is CASI Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: CASI's short term assets ($73.4M) exceed its short term liabilities ($6.9M).

Long Term Liabilities: CASI's short term assets ($73.4M) exceed its long term liabilities ($1.3M).


Debt to Equity History and Analysis

Debt Level: CASI is debt free.

Reducing Debt: CASI has no debt compared to 5 years ago when its debt to equity ratio was 166%.


Balance Sheet

Inventory Level: CASI has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if CASI's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CASI has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: CASI has less than a year of cash runway if free cash flow continues to reduce at historical rates of -66.5% each year


Next Steps

Dividend

What is CASI Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.1%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate CASI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate CASI's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CASI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CASI's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CASI's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of CASI Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

1.3yrs

Average management tenure


CEO

Wei-Wu He (54yo)

0.8yrs

Tenure

US$6,105,000

Compensation

Dr. Wei-Wu He, Ph.D. serves as Chairman and Chief Executive Officer at CASI Pharmaceuticals, Inc since April 2, 2019 and served as its Executive Chairman from February 23, 2018 until April 2, 2019. Dr. He  ...


Management Age and Tenure

1.3yrs

Average Tenure

53.5yo

Average Age

Experienced Management: CASI's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.


Board Age and Tenure

5.6yrs

Average Tenure

58yo

Average Age

Experienced Board: CASI's board of directors are considered experienced (5.6 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$64,00020 Aug 19
Wei-Wu He
EntityIndividual
Role
Chief Executive Officer
Chairman & CEO
Shares20,000
Max PriceUS$3.20
BuyUS$507,20015 Aug 19
Wei-Wu He
EntityIndividual
Role
Chief Executive Officer
Chairman & CEO
Shares160,000
Max PriceUS$3.17

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 23.3%.


Management Team

  • Wei-Wu He (54yo)

    Chairman & CEO

    • Tenure: 0.8yrs
    • Compensation: US$6.11m
  • Cynthia Hu (49yo)

    COO, General Counsel & Secretary

    • Tenure: 11.1yrs
    • Compensation: US$467.10k
  • Jim Goldschmidt

    Senior Vice President of Business Development

    • Tenure: 0.8yrs
  • Alex Zukiwski (62yo)

    Chief Medical Officer

    • Tenure: 2.8yrs
    • Compensation: US$612.01k
  • Sara Capitelli (53yo)

    VP of Finance & Principal Accounting Officer

    • Tenure: 9yrs
    • Compensation: US$222.19k
  • George Chi (50yo)

    Chief Financial Officer

    • Tenure: 1.3yrs
    • Compensation: US$1.61m
  • Larry Zhang (60yo)

    President

    • Tenure: 0.3yrs
    • Compensation: US$5.20m

Board Members

  • Quan Zhou (61yo)

    Independent Director

    • Tenure: 3.6yrs
    • Compensation: US$300.50k
  • James Huang (53yo)

    Independent Director

    • Tenure: 6.8yrs
    • Compensation: US$300.50k
  • Rajesh Shrotriya (75yo)

    Independent Director

    • Tenure: 5.3yrs
    • Compensation: US$212.85k
  • Wei-Wu He (54yo)

    Chairman & CEO

    • Tenure: 0.8yrs
    • Compensation: US$6.11m
  • S. Eckhardt

    Member of Scientific Advisory Board

    • Tenure: 13.5yrs
  • Alex Wu (55yo)

    Independent Director

    • Tenure: 6.8yrs
    • Compensation: US$212.85k
  • Ghassan Abou-Alfa

    Member of Clinical Advisory Board

    • Tenure: 4.5yrs
  • Franklin Salisbury (63yo)

    Independent Director

    • Tenure: 5.6yrs
    • Compensation: US$212.85k
  • Robert Mayer

    Member of Clinical Advisory Board

    • Tenure: 4.5yrs

Company Information

CASI Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: CASI Pharmaceuticals, Inc.
  • Ticker: CASI
  • Exchange: NasdaqCM
  • Founded: 1991
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$307.345m
  • Shares outstanding: 96.35m
  • Website: https://www.casipharmaceuticals.com

Number of Employees


Location

  • CASI Pharmaceuticals, Inc.
  • 9620 Medical Center Drive
  • Suite 300
  • Rockville
  • Maryland
  • 20850
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CASINasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJun 1996
ENMNDB (Deutsche Boerse AG)YesCommon StockDEEURJun 1996

Biography

CASI Pharmaceuticals, Inc., a pharmaceutical company, develops pharmaceutical products and various therapeutics in China, the United States, and internationally. The company’s product pipeline includes EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma. Its product pipeline also comprises ZEVALIN, an ibritumomab tiuxetan injection for intravenous use indicated for the treatment of patients with relapsed or refractory, low-grade, or follicular B-cell non-Hodgkin’s lymphoma, as well as for the treatment of patients with previously untreated follicular non-Hodgkin’s lymphoma; and MARQIBO, a microtubule inhibitor to treat adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. In addition, the company engages in the development of a portfolio of 26 FDA-approved abbreviated new drug applications (ANDAs), including entecavir and tenofovir disoproxil fumarate indicated for hepatitis B virus; and 4 pipeline ANDAs that are pending FDA approval. Further, it is involved in developing ENMD-2076, an Aurora A/angiogenic kinase inhibitor that has completed Phase II studies for solid tumors, as well as various proprietary early-stage immune-oncological potential candidates in preclinical development. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Rockville, Maryland. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/01/21 23:39
End of Day Share Price2020/01/21 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.